Close Window

References

  1. Guyton AC, Hall JE. Red blood cells, anemia, and polycythemia. In: Textbook of Medical Physiology. 11th ed. Philadelphia, PA: WB Saunders; 2006:419-428.
  2. Dessypris EN. Erythropoiesis. In: Lee GR, Foerster J, Lukens J, Wintrobe MM, eds. Wintrobe’s Clinical Hematology. Vol. 1. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1998:169-192.
  3. Papayannopoulou T, D’Andrea AD, Abkowitz JL, Migliaccio AR. Biology of erythropoiesis, erythroid differentiation, and maturation. In: Hoffman R, Benz EJ Jr, Shattil SJ, et al, eds. Hematology: Basic Principles and Practice. 4th ed. Philadelphia, PA: Elsevier Churchill Livingstone; 2005:267-294.
  4. Bunn H. Pathophysiology of the anemias. In: Isselbacher KJ, Wilson JD, Braunwald E, eds. Harrison’s Principles and Practice of Internal Medicine. 13th ed. New York, NY: McGraw-Hill; 1994:1717-1721.
  5. Hillman RS, Finch CA. General characteristics of the erythron. In: Hillman RS, Finch CA, eds. Red Cell Manual Edition. 7th ed. 1996. Philadelphia, PA: F.A. Davis Company; 1996:1-15.
  6. EPOGEN® (epoetin alfa) prescribing information, Amgen.
  7. Sargent JA, Acchiardo SR. Iron requirements in hemodialysis. Blood Purif. 2004;22:112-123.
  8. Uehlinger DE, Gotch FA, Sheiner LB. A pharmacodynamics model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther. 1992;51:76-89.
Return to Previous Page

EPOGEN® (epoetin alfa) stimulates erythropoiesis, and iron supports proper
heme formation1-5

Hypothetical model of the response to EPOGEN® 6-8

IMPORTANT SAFETY INFORMATION

  • Control hypertension prior to initiating and during treatment with EPOGEN®.
  • EPOGEN® increases the risk of seizures in patients with CKD. Monitor patients closely for new-onset seizures, premonitory symptoms, or change in seizure frequency.


Scroll down for additional Important Safety Information